Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.


Subscribe or Register

Existing user? Login


Transdermal buprenorphine poorly tolerated in people with dementia

A study of transdermal analgesics in people living with dementia has shown that more than half discontinue buprenorphine owing to adverse events.

Transdermal pain relief

Source: Science Photo Library

Using data from 162 people with advanced dementia and depression, researchers found that buprenorphine appeared to be poorly tolerated, even at the lowest initial dose

Research has found that more than half of people living with dementia who are treated with transdermal buprenorphine discontinue the drug because of adverse events[1].

The study involved 162 people living in nursing homes in Norway with advanced dementia and depression. They were randomly assigned to active analgesic treatment (acetaminophen/buprenorphine) or placebo for 13 weeks.

The findings, published in Clinical Interventions in Aging (16 May 2018), showed that 52.3% (n=23/44) of patients assigned to buprenorphine 5μg/hour discontinued therapy owing to adverse events, compared with 13.3% (n=6/45) of patients in the placebo group.

Neurological and psychiatric events were the most common type of adverse event in buprenorphine-treated patients.

The researchers said the findings indicated that buprenorphine was poorly tolerated in people with dementia, even at the lowest initial dose.

“When buprenorphine is administered to people with dementia, the patients’ general condition pre- and post-treatment should therefore be monitored carefully,” they concluded.

Citation: Clinical Pharmacist DOI: 10.1211/CP.2018.20205420

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Supplementary images

  • Transdermal pain relief

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.